JP2014510037A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510037A5
JP2014510037A5 JP2013549896A JP2013549896A JP2014510037A5 JP 2014510037 A5 JP2014510037 A5 JP 2014510037A5 JP 2013549896 A JP2013549896 A JP 2013549896A JP 2013549896 A JP2013549896 A JP 2013549896A JP 2014510037 A5 JP2014510037 A5 JP 2014510037A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
aryl
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549896A
Other languages
English (en)
Japanese (ja)
Other versions
JP5905028B2 (ja
JP2014510037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/050132 external-priority patent/WO2012098416A1/en
Publication of JP2014510037A publication Critical patent/JP2014510037A/ja
Publication of JP2014510037A5 publication Critical patent/JP2014510037A5/ja
Application granted granted Critical
Publication of JP5905028B2 publication Critical patent/JP5905028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013549896A 2011-01-21 2012-01-23 ジアリールアセチレンヒドラジドを含有するチロシンキナーゼ阻害剤 Active JP5905028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN184/MUM/2011 2011-01-21
IN184MU2011 2011-01-21
PCT/GB2012/050132 WO2012098416A1 (en) 2011-01-21 2012-01-23 Diarylacetylene hydrazide containing tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014510037A JP2014510037A (ja) 2014-04-24
JP2014510037A5 true JP2014510037A5 (enExample) 2015-03-12
JP5905028B2 JP5905028B2 (ja) 2016-04-20

Family

ID=45540888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549896A Active JP5905028B2 (ja) 2011-01-21 2012-01-23 ジアリールアセチレンヒドラジドを含有するチロシンキナーゼ阻害剤

Country Status (12)

Country Link
US (1) US9024021B2 (enExample)
EP (1) EP2665709B1 (enExample)
JP (1) JP5905028B2 (enExample)
KR (1) KR101892574B1 (enExample)
CN (1) CN103502217B (enExample)
AU (1) AU2012208388C1 (enExample)
BR (1) BR112013018212B1 (enExample)
CA (1) CA2825367C (enExample)
EA (1) EA024194B8 (enExample)
ES (1) ES2608829T3 (enExample)
MX (1) MX336051B (enExample)
WO (1) WO2012098416A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351123B2 (en) 2017-03-15 2022-06-07 Sun Pharma Advanced Research Company Limited Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
JP6744218B2 (ja) 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ebna1阻害剤およびそれらの使用方法
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
EP3297991B1 (en) * 2015-05-18 2020-01-29 Sun Pharma Advanced Research Company Ltd Novel amidoheteroaryl aroyl hydrazide ethynes
EP3418275B1 (en) * 2016-02-16 2021-03-17 Korea Institute of Science and Technology Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
EA037697B1 (ru) * 2016-06-02 2021-05-12 Сан Фарма Адвансед Ресёрч Компани Лимитед Лечение болезни паркинсона
RS63243B1 (sr) 2016-06-02 2022-06-30 Sun Pharma Advanced Res Co Ltd Lečenje parkinsonove bolesti
WO2018167803A1 (en) * 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide
TW201946919A (zh) 2018-05-17 2019-12-16 威斯塔研究所 Ebna1抑制劑晶形、其製備方法及其使用方法
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
JP2022536331A (ja) 2019-06-11 2022-08-15 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド シヌクレイノパチーの治療
MX2022007988A (es) * 2019-12-26 2022-07-11 Beijing Innocare Pharma Tech Co Ltd Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
WO2021172931A1 (ko) 2020-02-28 2021-09-02 재단법인 대구경북첨단의료산업진흥재단 3-((8-((1h-피라졸-4-일)아미노)이미다조[1,2-a]피리딘-3-일)에티닐)-n-페닐벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20230301982A1 (en) * 2020-07-31 2023-09-28 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease
TW202317530A (zh) 2021-06-29 2023-05-01 日商住友化學股份有限公司 雜環化合物及含有其之組成物之抗藥性有害節肢動物防除方法
EP4577213A1 (en) 2022-08-25 2025-07-02 Sun Pharma Advanced Research Company Ltd Methods of treating chronic myeloid leukemia using the tyrosine kinase inhibitor vodobatinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE602005017129D1 (de) * 2004-03-22 2009-11-26 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5-rezeptorantagonisten
EA034598B1 (ru) * 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351123B2 (en) 2017-03-15 2022-06-07 Sun Pharma Advanced Research Company Limited Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
US12194153B2 (en) 2017-03-15 2025-01-14 Sun Pharma Advanced Research Company Limited Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n′-(2-chloro-6-methyl-benzoyl) hydrazide

Similar Documents

Publication Publication Date Title
JP2014510037A5 (enExample)
JP2013522354A5 (enExample)
CN110730678B (zh) 包含alk抑制剂和shp2抑制剂的药物组合
JP2020527174A5 (enExample)
JP6746776B2 (ja) Toll様受容体調節剤化合物
KR102841843B1 (ko) 트리아졸로-피리미딘 화합물 및 그의 용도
RU2671628C2 (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1,2,4]ТРИАЗОЛО[1,5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
JP2022184886A5 (enExample)
JP2020504136A5 (enExample)
JP2016529292A5 (enExample)
JP2012515789A5 (enExample)
JP2013537210A5 (enExample)
JP2016537384A5 (enExample)
JP2019503337A5 (enExample)
JP2022500402A5 (enExample)
JP2016538316A5 (enExample)
JP2007522200A5 (enExample)
JP2010513523A5 (enExample)
JP2015511245A5 (enExample)
JP2013519707A5 (enExample)
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
KR20180056764A (ko) 비아릴 키나제 억제제
JP2004525149A5 (enExample)
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
AU2004312049A1 (en) Treatment of malignant gliomas with TFG-beta inhibitors